French pharma group

法国制药集团

Sanofi

赛诺菲

has agreed to buy US-based

已同意购买美国的

Blueprint Medicines Corporation

蓝图医药公司

, a

，一个

biopharmaceutical company

生物制药公司

specializing in systemic mastocytosis, a rare immunological disease, the companies said on Monday.

公司周一表示，专门针对系统性肥大细胞增多症，这是一种罕见的免疫疾病。

Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash, representing an equity value of approximately $9.1 billion.

根据收购条款，赛诺菲将每股支付129.00美元现金，股权价值约为91亿美元。

The acquisition 'represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company,' said Sanofi CEO Paul Hudson.

赛诺菲首席执行官保罗·哈德森表示：“此次收购代表了我们在罕见病和免疫学领域的战略前进步骤。它增强了我们的研发管线，并加速我们转变为全球领先的免疫学公司。”

The deal will add to Sanofi's portfolio the rare immunology disease drug

这笔交易将为赛诺菲的产品组合增加罕见免疫疾病药物。

Ayvakit/Ayvakyt

阿伐普利/阿伐替尼

(avapritinib), approved in the US and the EU, and a promising advanced and early-stage

（阿伐普利尼），已在美国和欧盟获得批准，且在晚期和早期阶段均有良好的前景

immunology pipeline

免疫学管道

.

。

Blueprint's established presence among allergists, dermatologists, and immunologists is also expected to enhance Sanofi's growing immunology pipeline, the companies said.

公司表示，蓝图生物在过敏科、皮肤科和免疫科医生中的既定地位也有望增强赛诺菲不断增长的免疫学产品线。

Live Events

现场活动

Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis, a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs.

Ayvakit/Ayvakyt 是唯一获批用于治疗晚期和惰性系统性肥大细胞增多症的药物，这是一种罕见的免疫疾病，其特征是骨髓、皮肤、胃肠道及其他器官中异常肥大细胞的积累和激活。

The acquisition will also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology.

此次收购还将带来用于系统性肥大细胞增多症的下一代药物elenestinib，以及BLU-808——一种高效且具有高度选择性的口服野生型KIT抑制剂，有望治疗广泛免疫学相关疾病。

Besides $129.00 per share in cash at the closing of the deal, Blueprint shareholders will also receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808..

除了在交易结束时每股 129.00 美元的现金外，Blueprint 的股东还将获得一份不可交易的或有价值权（CVR），持有人将有权因未来 BLU-808 的开发和监管里程碑成就而分别获得每份 CVR 2 美元和 4 美元的两笔潜在里程碑付款。

The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis.

包括潜在的CVR支付在内，该交易的总股权价值在完全稀释的基础上约为95亿美元。

Hudson said the deal complements recent acquisitions of other early-stage medicines that remain Sanofi's main field of interest and added that Sanofi still retains a sizeable capacity for further acquisitions.

哈德逊表示，这笔交易补充了最近对其他早期药物的收购，这些药物仍然是赛诺菲的主要兴趣领域，并补充说赛诺菲仍有相当大的能力进行进一步的收购。

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)